Skip to main content
. 2005 Aug 25;115(9):2351–2362. doi: 10.1172/JCI24177

Figure 7.

Figure 7

Severe reduction in hDido expression in bone marrow from MDS/MPD, MDS, and CMPD patients. (A) Relative hDido1, hDido2, and hDido3 expression levels were determined by real-time quantitative PCR. Ct increments relative to those of samples from a pool of healthy donors and actin (ΔΔCt) are shown for indicated patients. Note that a value of 3 in Ct increments indicates a 10-fold decrease in expression. (B) Northern blot analysis of hDido1, hDido2, and hDido3 expression in bone marrow samples of a healthy control donor (Ctl) and patients, indicated by numbers, diagnosed with various myeloid disorders. The blot was stained with methylene blue to control RNA loading. Positions of hDido transcripts and 28s and 18s RNA are indicated. Diagnosis of patients was as follows: chronic myelomonocytic leukemia (MDS/MPD), patients 15, 24, 25; refractory anemia (MDS), patients 2, 12, 17, 26, 30; polycythemia vera (CMPD), patients 7, 30; essential thrombocythemia (CMPD), patient 6; and refractory anemia with ringed sideroblasts (MDS), patient 23.